- The Three Switches Behind the “Five Faces”: Why Subtype Decides Treatment and Path
# EN｜The Three Switches Behind the “Five Faces”: Why Subtype Decides Treatment and Path In our fir […]
- How Cancer Grows: From a Single Cell to the Doorway of Metastasis — The Four Turning Points of a “Growth Story”
# EN｜How Cancer Grows: From a Single Cell to the Doorway of Metastasis — The Four Turning Points of a “G […]
- Why a Branching “Tree” Turns Cancerous: Reading the Entrance to Cancer Through Cells, DNA, and Hormones
# EN｜Why a Branching “Tree” Turns Cancerous: Reading the Entrance to Cancer Through Cells, DNA, an […]
- Who Develops Breast Cancer, When, and Why: Five Handholds for Reading Risk—and How to Use “Relative Risk” Correctly
# EN｜Who Develops Breast Cancer, When, and Why: Five Handholds for Reading Risk—and How to Use “Relative […]
- Breast Cancer Is Not One Disease: The Big Picture and Its “Five Faces” in an Era of 1-in-8
# EN｜Breast Cancer Is Not One Disease: The Big Picture and Its “Five Faces” in an Era of 1-in-8 Ac […]
- Oncology Drug Approval News Flash: FDA Approves Nilotinib Orally Disintegrating Tablets (Cavhanza, Cycle Pharmaceuticals) for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
On June 2, 2026, the U.S. Food and Drug Administration (FDA) approved Cavhanza (Cycle Pharmaceuticals), an ora […]
- The Last Mile to Deliver Breakthroughs Worldwide — How Equity, Liquid Biopsy, and AI Are Rewriting Cancer-Care Implementation
This is the sixth and final installment of the ASCO 2026 in Review series. Of the “five turning points&# […]
- Will GLP-1 Change Cancer? — The State of Play on the New Battlefield of Metabolism x Oncology
This is the fifth installment of our ASCO 2026 in Review series. Among the five turning points laid out in the […]
- Can Bispecific Antibodies Break the ‘Keytruda Ceiling’? — Three Directions Revealed by PD-1xVEGF
This is the fourth installment of our ASCO 2026 in Review series. Of the “five turning points” map […]
- Antibody-Drug Conjugates Break the Tumor-Type Barrier — Reading the 2026 Drug-Development Map Through the Race for Targets
This is the third installment of our ASCO 2026 in Review series. Of the “five turning points” laid […]
# EN｜The Three Switches Behind the “Five Faces”: Why Subtype Decides Treatment and Path In our fir […]
